Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis

被引:8
|
作者
Ohashi, Kadoaki [1 ]
Ninomiya, Kiichiro [1 ]
Yoshioka, Hiroshige [2 ,20 ]
Bessho, Akihiro [3 ]
Shibayama, Takuo [4 ]
Aoe, Keisuke [5 ]
Ishikawa, Nobuhisa [6 ]
Kozuki, Toshiyuki [7 ]
Kawai, Haruyuki [8 ]
Kuyama, Shoichi [9 ]
Miyoshi, Seigo [10 ]
Fujitaka, Kazunori [11 ]
Obata, Hideto [12 ]
Tsubata, Yukari [13 ]
Awaya, Yoshikazu [14 ]
Inoue, Masaaki [15 ]
Inoue, Koji [16 ]
Horita, Naokatsu [17 ]
Yanai, Hiroyuki [18 ]
Hotta, Katsuyuki [19 ]
Kiura, Katsuyuki [1 ]
机构
[1] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[2] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan
[3] Japanese Red Cross Okayama Hosp, Dept Resp Med, Okayama, Japan
[4] Natl Hosp Org, Dept Resp Med, Okayama Med Ctr, Okayama, Japan
[5] Natl Hosp Org, Dept Med Oncol, Yamaguchi Ube Med Ctr, Ube, Yamaguchi, Japan
[6] Hiroshima Prefectural Hosp, Dept Resp Med, Hiroshima, Japan
[7] Natl Hosp Org, Shikoku Canc Ctr, Dept Thorac Oncol & Med, Shikoku, Ehime, Japan
[8] Okayama Saiseikai Gen Hosp, Dept Internal Med, Okayama, Japan
[9] Iwakuni Med Ctr, Dept Resp Med, Iwakuni, Japan
[10] Ehime Univ, Grad Sch Med, Dept Cardiol Pulmonol Hypertens & Nephrol, Matsuyama, Ehime, Japan
[11] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan
[12] Yamaguchi Ken Saiseikai Shimonoseki Gen Hosp, Dept Resp Med, Shimonoseki, Yamaguchi, Japan
[13] Shimane Univ, Fac Med, Div Med Oncol & Resp Med, Dept Internal Med, Matsue, Shimane, Japan
[14] Miyoshi Cent Hosp, Dept Resp Med, Saitama, Japan
[15] Shimonoseki City Hosp, Dept Chest Surg, Shimonoseki, Yamaguchi, Japan
[16] Ehime Prefectural Cent Hosp, Dept Resp Med, Matsuyama, Ehime, Japan
[17] Kure Kyosai Hosp, Dept Resp Med, Kure, Hiroshima, Japan
[18] Okayama Univ Hosp, Dept Pathol, Okayama, Japan
[19] Okayama Univ Hosp, Ctr Innovat Clin Med, 2-5-1 Shikata Cho Kita Ward, Okayama 7008558, Japan
[20] Kansai Med Univ Hosp, Dept Thorac Oncol, Hirakata, Osaka, Japan
关键词
Epidermal growth factor receptor mutations; Performance status; Human epidermal growth factor receptor-2; Time-To-Treatment failure; GROWTH-FACTOR RECEPTOR; ACQUIRED-RESISTANCE; TRASTUZUMAB EMTANSINE; GENE-MUTATIONS; PHASE-II; CANCER; MUTANT; AMPLIFICATION; OVEREXPRESSION; ADENOCARCINOMA;
D O I
10.1016/j.lungcan.2020.09.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard treatment for EGFR-mutated non-small-cell lung carcinoma (NSCLC); however, a biomarker to predict their efficacy has not been established. Although human epidermal growth factor receptor-2 (HER2) aberrations constitute a potential mechanism for acquired resistance to EGFR-TKIs, the impact of HER2 on EGFR-TKI treatment outcomes has not been systematically evaluated. In this post-hoc subgroup study, we examined the impact of HER2 on the effect of EGFR-TKIs in patients with NSCLC harboring EGFR mutations. Materials and Methods: Of 1126 patients with NSCLC enrolled into a prospective cohort study (HER2-CS study), we analyzed data of 356 (32 %) patients with EGFR-mutant tumors. HER2 protein expression levels were determined by immunohistochemistry (IHC) with the gastric cancer criteria. Patients were divided either to an HER2-P group (HER2-IHC2+/3+) or an HER2-N group (HER2-IHC0/1+). We primarily assessed differences in the time-to-treatment failure (TTF) of EGFR-TKI between the groups. Results: The HER2 scoring was as follows: IHC0 (n = 76, 21 %), IHC1+ (n = 199, 56 %), IHC2+ (n = 72, 20 %), and IHC3+ (n = 9, 3 %). The patients' demographics were similar in the HER2-P and HER2-N groups. The HER2-P group showed a significantly shorter EGFR-TKI TTF than the HER2-N group (hazard ratio [HR]: 1.657, 95 % confidence interval [CI]: 1.076-2.552; median: 13.3 vs. 19.1 months). The magnitude of the negative impact of TTF was especially dependent on performance status (PS). HER2 expression significantly deteriorated the TTF in the subgroup with PS 2 (HR: 5.497, 95 % CI: 1.510-20.02), but not in that with better PS (HR: 1.437, 95 % CI: 0.899-2.298) (pinteraction = 0.015). Conclusion: In the current cohort, HER2 protein expression in EGFR-mutant NSCLC may have a negative impact on the effect of EGFR-TKIs, the effect of which was PS dependent.
引用
收藏
页码:83 / 89
页数:7
相关论文
共 50 条
  • [1] Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations:A HER2-CS STUDY subset analysis.
    Kayatani, Hiroe
    Aoe, Keisuke
    Ohashi, Kadoaki
    Yoshioka, Hiroshige
    Bessho, Akihiro
    Ishikawa, Nobuhisa
    Yamasaki, Masahiro
    Kozuki, Toshiyuki
    Fujimoto, Nobukazu
    Ueda, Yutaka
    Bandoh, Syuuji
    Murakami, Isao
    Ichikawa, Hirohisa
    Kubota, Tetsuya
    Sugimoto, Keisuke
    Takigawa, Nagio
    Sumikawa, Takashi
    Kiura, Katsuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] ACTIVITY OF BIBW 2992, AN IRREVERSIBLE EGFR/HER1 AND HER2 TKI, IN LUNG ADENOCARCINOMA PATIENTS HARBORING LESS COMMON EGFR MUTATIONS
    Shih, J.
    Yu, C.
    Su, W.
    Hsia, T.
    Graziano, S. L.
    Calvo, R.
    Cong, X. J.
    Shahidi, M.
    Yang, C.
    Miller, V.
    ANNALS OF ONCOLOGY, 2010, 21 : 138 - 138
  • [3] A large prospective cohort study of the clinical features of advanced lung cancer harboring HER2 aberrations (HER2-CS STUDY)
    Tanaka, T.
    Yoshioka, H.
    Bessho, A.
    Ishikawa, N.
    Yamasaki, M.
    Shibayama, T.
    Aoe, K.
    Kozuki, T.
    Fujimoto, N.
    Genba, K.
    Ueda, Y.
    Inoue, M.
    Murakami, T.
    Kuyama, S.
    Kawai, H.
    Fujitaka, K.
    Inoue, K.
    Takata, M.
    Yanai, H.
    Kiura, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Clinical Features of Advanced Lung Cancer Harboring HER2 Aberrations: A Large Prospective Cohort Study (HER2-CS STUDY)
    Hosokawa, S.
    Bessho, A.
    Ninomiya, K.
    Tanaka, T.
    Ishikawa, N.
    Yamasaki, M.
    Shibayama, T.
    Aoe, K.
    Kozuki, T.
    Fujimoto, N.
    Gemba, K.
    Ueda, Y.
    Inoue, M.
    Murakami, T.
    Kuyama, S.
    Kawai, H.
    Fujitaka, K.
    Inoue, K.
    Takata, M.
    Yanai, H.
    Hotta, K.
    Kiura, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1777 - S1777
  • [5] A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)
    Ninomiya, Kiichiro
    Hata, Tae
    Yoshioka, Hiroshige
    Ohashi, Kadoaki
    Bessho, Akihiro
    Hosokawa, Shinobu
    Ishikawa, Nobuhisa
    Yamasaki, Masahiro
    Shibayama, Takuo
    Aoe, Keisuke
    Kozuki, Toshiyuki
    Harita, Shingo
    Ueda, Yutaka
    Murakami, Toshi
    Fujimoto, Nobukazu
    Yanai, Hiroyuki
    Toyooka, Shinichi
    Takata, Minoru
    Hotta, Katsuyuki
    Kiura, Katsuyuki
    Gemba, K.
    Ikeda, G.
    Yasugi, M.
    Kurimoto, E.
    Nakano, K.
    Moritaka, T.
    Inoue, K.
    Miyoshi, S.
    Hamaguchi, N.
    Ito, R.
    Sano, Y.
    Takata, I
    Mitani, A.
    Nishisaka, T.
    Shoda, H.
    Nishida, A.
    Tamamoto, S.
    Fujitaka, K.
    Masuda, T.
    Miyamoto, S.
    Hattori, N.
    Sugimoto, K.
    Fujii, S.
    Ueda, Y.
    Sakugawa, M.
    Fukamatsu, N.
    Ogata, Y.
    Bandoh, S.
    Kanaji, N.
    Takigawa, N.
    CHEST, 2019, 156 (02) : 357 - 366
  • [6] HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
    Gan, Jiadi
    Huang, Yihua
    Liao, Jun
    Pang, Lanlan
    Fang, Wenfeng
    ONCOTARGETS AND THERAPY, 2021, 14 : 5297 - 5307
  • [7] Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations
    Choi, Junyoung
    Yoon, Shinkyo
    Kim, Deokhoon
    Moon, Yong Wha
    Lee, Chang Hoon
    Seo, Seyoung
    Cheon, Jaekyung
    Gho, Yong Song
    Kim, Changhoon
    Lee, Eung Ryoung
    Kim, Soo-Youl
    Lee, Kyoungmin
    Ha, Joo Young
    Park, Sook Ryun
    Kim, Sang-We
    Park, Kang-Seo
    Lee, Dae Ho
    AMERICAN JOURNAL OF CANCER RESEARCH, 2019, 9 (08): : 1708 - +
  • [8] Clinical Characteristics of NoneSmall Cell Lung Cancer Harboring Mutations in Exon 20 Of EGFR or HER2
    Takeda, M.
    Sakai, K.
    Hayashi, H.
    Tanaka, K.
    Tanizaki, J.
    Takahama, T.
    Haratani, K.
    Nishio, K.
    Nakagawa, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S903 - S903
  • [9] Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer
    Liu, Bin
    Chen, Deng
    Chen, Shipeng
    Saber, Ali
    Haisma, Hidde
    BIOCHEMICAL PHARMACOLOGY, 2020, 178
  • [10] EGFR, HER2, and HER3 Expression in Laryngeal Primary Tumors and Corresponding Metastases
    Qichun Wei
    Liming Sheng
    Yongjie Shui
    Qiongge Hu
    Hans Nordgren
    Jorgen Carlsson
    Annals of Surgical Oncology, 2008, 15 : 1193 - 1201